BCG-SSI® vaccine-associated lymphadenitis: Incidence and management
Material and methods: The study included 194 patients. All patients had received the BCGSSI ® vaccine during the first week of life routinely or at a later time according to the indications. The indications for surgical treatment were lymph node destruction also affecting the skin. All patients in this study received surgical treatment – the affected lymph node extirpation.
Results: The mean age of the patients was 5.12 0.96 months. A total of 172 patients had purulent axillar lymphadenitis, 14 had purulent supraclavicular lymphadenitis, 8 patients had lymphadenitis at both localizations. During the whole study period the incidence of BCG adenitis varied from 0.02% to 0.36%, while the mean rate was 0.11% 0.08% from 184,068 vaccinated children during the study period. We observed an increasing trend in the incidence of BCG lymphadenitis during the study period. The primary and complete healing rate at the end of period was 99.5% (n = 193) following an affected lymph node extirpation. The mean hospitalization time after the operation was 3.71 0.18 days.
Conclusions: The incidence of BCG-SSI® vaccine associated purulent lymphadenitis varied widely with an increasing trend, followed by the return to the product characteristic limits. Indications for the surgical treatment should not be changed. Extirpation of the purulent BCG adenitis is a safe treatment method and leads to the primary wound healing in the majority of cases.
Engelis, A.; Kakar, M.; Meikšāns, R.; Petersons, A. BCG-SSI® vaccine-associated lymphadenitis: Incidence and management. Medicina 2016, 52, 187-191.
Engelis A, Kakar M, Meikšāns R, Petersons A. BCG-SSI® vaccine-associated lymphadenitis: Incidence and management. Medicina. 2016; 52(3):187-191.Chicago/Turabian Style
Engelis, Arnis; Kakar, Mohit; Meikšāns, Roberts; Petersons, Aigars. 2016. "BCG-SSI® vaccine-associated lymphadenitis: Incidence and management." Medicina 52, no. 3: 187-191.